The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Chimerix (CMRX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Chimerix is a member of the Medical sector. This group includes 909 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CMRX is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CMRX's full-year earnings has moved 13.18% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, CMRX has moved about 2.96% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 0.12% on average. As we can see, Chimerix is performing better than its sector in the calendar year.
Breaking things down more, CMRX is a member of the Medical - Products industry, which includes 86 individual companies and currently sits at #102 in the Zacks Industry Rank. On average, this group has gained an average of 0.42% so far this year, meaning that CMRX is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CMRX as it looks to continue its solid performance.